Search:
You do not have permission to access this chart.
Please Sign Up or Login
News for Alterity Therapeutics Limited (ATHE)
minutes ago | Banggood.com
58 minutes ago | Aliexpress.com
a week ago | PRNewsWire
a week ago | Pulse2
2 weeks ago | PRNewsWire
a month ago | PRNewsWire
a month ago | Pulse2
a month ago | Proactive Investors
a month ago | Pulse2
a month ago | PRNewsWire
a month ago | PRNewsWire
3 months ago | PRNewsWire
Alterity Therapeutics Limited researches and develops therapeutic drugs for the treatment of Parkinsonian’s disease and other neurodegenerative diseases in Australia. The company’s lead drug candidates is ATH434 that has completed Phase I clinical trial for the treatment of Parkinson’s disease. It is also developing PBT2 for used as an antimicrobial agent. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. The company was founded in 1997 and is based in Melbourne, Australia.
Sector:
HealthcareIndustry:
BiotechnologyEmployees:
12Address:
Alterity Therapeutics Limited 460 Bourke Street Level 3 Melbourne VIC 3000 AustraliaWebsite:
Home